-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical network September 24th, recently, NMPA official website data show that Hesco's Pescopristamin tablets 4 imitation listing applications into the "in the approval" stage, is expected to usher in good news in the near future.
pyridine tablets as a drug for the renin-angiotensin system, and the adaptation is hypertension and congesitive heart failure.
Figure 1: Hesco's Pypsypristamin tablet registration Source: NMPA's official website, Pythalpyristamin tablets for the treatment of hypertension and congestive heart failure, the product is a nonbly long-acting ACEI inhibitor, is no. Three generations of angiosin conversion enzyme inhibitors (ACE-I inhibitors), compared with other ACEI inhibitors, slow-acting but the most inhibitory effect of ACEI in the brain, good tolerance, do not cause high blood sugar, no adverse effects on blood lipids, good safety. figure
Figure 2: Domestic enterprises to obtain approval for the Python-Priscamine tablet Source: Minetrain one-click retrieval of Mi-Net data shows that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal, Pei Puli Sales of statin tablets rose from 500 million yuan in 2015 to 760 million yuan in 2019, there are currently two approved enterprises, no enterprise evaluation, if Haisco was approved will successfully become the first enterprise to evaluate the product.
Figure 3: Sales of Pythapridapaamine tablets Source: Minet China's public medical institutions terminal competition pattern Haisco currently has another treatment of primary hypertension products declared on the market and in review, Pei pulidapaamine tablets in China's public medical institutions terminal is a sales of more than 200 million products, the current market only Schweija (Tianjin) pharmaceutical approval (for the original research and production of the first evaluation), Haisco is expected to impact the product's first imitation.
source: NMPA official website, Minet database review data statistics as of September 23, 2020.
